^
Association details:
| Biomarker: | RET wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Published date:
11/16/2023
Excerpt:
...we report on a 69-year-old man with recurrent NSCLC harboring high-level wild-type RET amplification (22-28 copies) as the only identified putative genomic driver who experienced both a systemic and intracranial confirmed response to the RET inhibitor selpercatinib.
DOI:
10.1200/PO.23.00295
